658 filings
Page 9 of 33
6-K
n22wkq3gmopcl yku4
1 Jun 20
Immutep Receives A$ 3.6 Million R&D Tax Incentive from French Government
12:00am
6-K
46yijpx9d2t jigvfbr
28 May 20
Current report (foreign)
12:00am
6-K
69aywfrlny
7 May 20
Immutep Granted Japanese Patent for Eftilagimod Alpha
9:02pm
6-K
zrkj lzp0
30 Apr 20
Immutep Announces FirstINSIGHT-004 Data and NewTACTI-002 Data to be
8:55pm
6-K
o3elw7oh1w
30 Apr 20
Not for release to US wire services or distribution in the United States
6:20am
6-K
q8684e gb
29 Apr 20
Immutep Reports Positive Phase IITACTI-002 Data
12:00am
6-K
e6l0geh2e 3q
23 Apr 20
Enrollment completed for theINSIGHT-004 Study
12:00am
6-K
nujp9yz7
21 Apr 20
Immutep Quarterly Activities ReportĀ & Appendix 4C
6:10am
6-K
gswicx6fpmiz34s6f6j
16 Apr 20
Current report (foreign)
8:50pm
6-K
8eaqtene 9a
14 Apr 20
ImmutepTACTI-002 Data Presentation
7:45pm
6-K
2cer 407bg8477f
8 Apr 20
Current report (foreign)
6:08am
6-K
ou59zf sjtiqfgft
30 Mar 20
Immutep AIPAC Phase IIb Clinical Results
12:00am
6-K
36ip4bfsbbpnp75y9j
27 Mar 20
Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data
9:26am
6-K
xmtljowbfgl7
20 Mar 20
Reports Completion of Recruitment of Phase I Study of Efti
9:42pm
6-K
ynut 3kfqh
17 Mar 20
Current report (foreign)
12:00am
6-K
5m8b pmkbt
10 Mar 20
Immutep Receives Second IND approval for Efti from US FDA
12:00am
6-K
0d5l45
24 Feb 20
Interim Financial Report
4:02pm
6-K
5wzcwgh3wr9mn
21 Feb 20
Immutep Reports PositiveTACTI-002 Data
12:00am
6-K
bwbtbj9b3nuwa91t
5 Feb 20
Immutep to PresentTACTI-002 Interim Data at German Cancer Congress
12:00am
6-K
3eu9itwtb
30 Jan 20
Quarterly report for entities subject to Listing Rule 4.7B
12:00am